Progress in our understanding of the role of GluA1 and GluA1‐containing AMPARs in the brain will undoubtedly shed light on novel therapeutic strategies for the treatment of dementia and age‐related cognitive disorders like AD. This evidence concerns the gene GRIA1 and Alzheimer disease.